All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Bristol Myers Squibb, the most common co-covered peer. The tracked stories average 2 original sources each. Eliquis appears in 1 tracked Healthcare story from July 8, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Eliquis
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Bristol Myers Squibb, the most common co-covered peer. The tracked stories average 2 original sources each. Eliquis appears in 1 tracked Healthcare story from July 8, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Eliquis. Shared-story counts are live from our verified record — not editorial picks.
Pfizer and Bristol Myers Squibb combine high dividend yields with deep healthcare pipelines, offering a compelling income-entry into a sector facing patent cliffs but also rich in innovation. For healthcare investors, the stocks demand a long-term view on drug development amid evolving policy risks.